Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00413 ...
Drug Name Pramipexole
Molecular Weight 211.327
Molecular Formula C10H17N3S
CAS Number 104632-26-0
SMILES CCCN[C@H]1CCC2=C(C1)SC(N)=N2
External Links
DRUGBANK DB00413
T3DB T3D2783
PubChem Compound 119570
PDR 1745
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 1.42 - 1.42 - https://pdf.hres.ca/dpd_pm/00043389.PDF
Boiling Point 378.0 ℃ 378 ℃ https://www.lookchem.com/Pramipexole/
Melting Point 289.0 ℃ 288-290 ℃ https://www.chemicalbook.com/ChemicalProductProperty_US_CB0486178.aspx
pKa 5.6 - 5.6,9.5 - https://pdf.hres.ca/dpd_pm/00043389.PDF
pKa 9.5 - 5.6,9.5 - https://pdf.hres.ca/dpd_pm/00043389.PDF
Log S -3.2 - -3.2 - http://www.t3db.ca/toxins/T3D2783

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 90.0 % >90 % DRUGBANK
Bioavailability 90.0 % >90 % PO, oral; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 1.6 ng/ml 1.6±0.23 ng/ml PO, oral; Male, men; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 2.1 ng/ml 2.1±0.25 ng/ml PO, oral;  Female, women; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 1.5 h 1-2 h PO, oral; normal,healthy; The Pharmacological Basis of Therapeutics
Metabolic 0 % ~0 % DRUGBANK
Clearance 24.0 L/h 400.0 ml/min DRUGBANK
Clearance 0.49 L/h/kg 8.2±1.4 ml/min/kg apparent clearance; normal,healthy; Male, men;  Female, women; Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;Parkinson ↓ ; The Pharmacological Basis of Therapeutics
Clearance 0.43 L/h/kg 7.2 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 500.0 L ~500 L DRUGBANK
Volume of Distribution 7.3 L/kg 7.3±1.7 L/kg Apparent volume of distribution; normal,healthy; Male, men;  Female, women; The Pharmacological Basis of Therapeutics
Volume of Distribution 7.0 L/kg 7 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 10.3 h ~8.5-12 h DRUGBANK
Half-life 11.6 h 11.6±2.57 h normal,healthy; adults; Male, men;  Female, women; RD, renal impairment, Renal disease，including uremia ↑ ;Age ↑ ; The Pharmacological Basis of Therapeutics
Half-life 12.4 h 12.4 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 800.0 mg/kg >800 mg/kg PO, oral; Rattus, Rat; DRUGBANK
Eliminate Route 90.0 % 90 % Urinary excretion; DRUGBANK
Eliminate Route 90.0 % ~90 % Urinary excretion; adults; normal,healthy; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 15.0 % ~15 % plasma proteins; DRUGBANK
Protein Binding 15.0 % 15 % adults; normal,healthy; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for adults 4.5 mg/day 4.5 mg/day PO, oral Mirapex pramipexole dihydrochloride PDR
Max dose for geriatric 4.5 mg/day 4.5 mg/day PO, oral Mirapex pramipexole dihydrochloride PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1